Amarin Corporation plc (AMRN)

Market Cap	259.67M
Revenue (ttm)	214.11M
Net Income (ttm)	-87.93M
Shares Out	20.71M
EPS (ttm)	-4.40
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	128,974
Open	13.32
Previous Close	13.33
Day's Range	12.41 - 13.32
52-Week Range	7.08 - 16.37
Beta	0.72
Analysts	Strong Sell
Price Target	7.00 (-44.18%)
Earnings Date	Jul 30, 2025

About AMRN

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty pharmacy providers. The company has a collaboration...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• IPO Date: Apr 1, 1993
• Employees: 275
• Stock Exchange: NASDAQ
• Ticker Symbol: AMRN
• Website: https://www.amarincorp.com

Financial Performance

In 2024, Amarin Corporation's revenue was $228.61 million, a decrease of -25.51% compared to the previous year's $306.91 million. Losses were -$82.18 million, 39.0% more than in 2023.

Analyst Forecast

According to one analyst, the rating for AMRN stock is "Strong Sell" and the 12-month stock price forecast is $7.0.

Price Target

$7.0

(-44.18% downside)

Analyst Consensus: Strong Sell